Effect of Adding PNF to IMT on Weaning Off MV (NCT07536347) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Effect of Adding PNF to IMT on Weaning Off MV
93 participantsStarted 2026-04-25
Plain-language summary
the goal of this clinical trial is to find out the effect of adding proprioceptive neuromuscular facilitation to inspiratory muscle training on weaning off mechanical ventilation. the main question it aims to answer is is there a significant difference in the effect of inspiratory muscle training combined with PNF on the duration of weaning in the mechanically ventilated ICU patients.
researchers will compare effect of (Inspiratory muscle training combined with PNF) to (Inspiratory muscle training) and control group.
participants will be mechanically ventilated both sexes patients will be recruited in this study from intensive care unit, their ages older than 18 years. The selected patients will be mechanically ventilated due to respiratory failure and will randomly assigned into three equal groups.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults of both sexes
* patients older than 18 years
* Conscious and cooperative
* Hemodynamic stability without significant vasopressor support.
* No continuous sedation.
* Mechanically ventilated due to type 1 or type 2 respiratory failure (RF) for at least 24 hours.
* Mechanically ventilated in assisted ventilation mode
* Are able to participate in training actively, weanable as regard shallow breathing index.
* presence of weaning criteria as defined in the European Consensus Conference in 2007, including sedation reduction, spontaneous breathing cycles, Partial pressure of oxygen (PaO2)/ fraction of inspired oxygen (FiO2) ≥ 150, absence of inotropes or vasopressors at high doses or increasing doses (\< 1 mg/h), oxy-hemoglobin saturation (SaO2) \> 90% with FiO2≤ 50%, positive end expiratory pressure (PEEP) ≤ 8 cmH2O, temperature between 36 and 39 °C.
Exclusion Criteria:
* Hemodynamic or respiratory instability
* Condition that can compromise weaning, such as heart failure.
* Condition that can prevent adequate performance of inspiratory muscle training, such as neuropathy or myopathy.
* Thoracic or abdominal surgery precluding the use of PNF exercises
* Rib fractures
* Current pregnancy
* Cardiac arrest with a guarded neurological prognosis
* Deep coma
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
• Time to Successful weaning
Timeframe: From enrollment to the end of treatment (an average of 7 to 14 days)
2
• Maximum inspiratory pressure
Timeframe: From enrollment to the end of treatment (an average of 7 to 14 days)
3
• Diaphragmatic excursion
Timeframe: From enrollment to the end of treatment (an average of 7 to 14 days)